Proton pump inhibitors may enhance the risk of citalopram‐ and escitalopram‐associated sudden cardiac death among patients receiving hemodialysis-Reference-Cited by-同舟云学术

Proton pump inhibitors may enhance the risk of citalopram‐ and escitalopram‐associated sudden cardiac death among patients receiving hemodialysis

Published:2022-03-24 Issue:6 Volume:31 Page:670-679
ISSN:1053-8569
Container-title:Pharmacoepidemiology and Drug Safety
language:en
Short-container-title:Pharmacoepidemiology and Drug

Author:

Assimon Magdalene M.¹,Pun Patrick H.²³,Al‐Khatib Sana M.³⁴,Brookhart M. Alan⁵,Gaynes Bradley N.⁶⁷,Winkelmayer Wolfgang C.⁸,Flythe Jennifer E.¹⁹

Affiliation:

1. University of North Carolina Kidney Center, Division of Nephrology and Hypertension, Department of Medicine UNC School of Medicine Chapel Hill North Carolina USA

2. Division of Nephrology, Department of Medicine Duke University School of Medicine Durham North Carolina USA

3. Duke Clinical Research Institute Durham North Carolina USA

4. Division of Cardiology Duke University Medical Center Durham North Carolina USA

5. Department of Population Health Sciences Duke University School of Medicine Durham North Carolina USA

6. Department of Psychiatry UNC School of Medicine Chapel Hill North Carolina USA

7. Department of Epidemiology UNC Gillings School of Global Public Health Chapel Hill North Carolina USA

8. Selzman Institute for Kidney Health, Section of Nephrology Baylor College of Medicine Houston Texas USA

9. Cecil G. Sheps Center for Health Services Research University of North Carolina Chapel Hill North Carolina USA

Funder

National Institutes of Health

National Heart, Lung, and Blood Institute

Publisher

Wiley

Subject

Pharmacology (medical),Epidemiology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/pds.5428

Reference44 articles.

1. Management of Polypharmacy in Dialysis Patients

2. Medication Reconciliation: The Foundation of Medication Safety for Patients Requiring Dialysis

3. Assessment of drug-drug interactions among renal failure patients of nephrology ward in a south Indian tertiary care hospital

4. Evaluation of potential drug- drug interactions among Palestinian hemodialysis patients

5. Adverse Drug Events in Patients with Chronic Kidney Disease Associated with Multiple Drug Interactions and Polypharmacy

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Authors' Reply: Pharmacokinetic Issue May Influence the Perceived Cardiac Risk Posed by Ondansetron in Patients Undergoing Chronic Hemodialysis;Journal of the American Society of Nephrology;2024-05-20

2. Prescription and Dispensation of QT-Prolonging Medications in Individuals Receiving Hemodialysis;JAMA Network Open;2024-04-30

3. Ondansetron and the Risk of Sudden Cardiac Death among Individuals Receiving Maintenance Hemodialysis;Journal of the American Society of Nephrology;2024-02-27

4. Evaluation of Appropriate Use of Proton Pump Inhibitors in Non-critically Ill Patients in Tertiary Medical Center: A Retrospective Study;Current Drug Safety;2024-02-09

5. Hypocalcemia: a cardiovascular risk factor coming of age?;Nephrology Dialysis Transplantation;2023-11-01